The effect of anti-L-selectin (aselizumab) in multiple traumatized patients—Results of a phase II clinical trial*

Abstract

Aselizumab was associated with a higher rate of infections and leucopenia; however, this difference was not significantly different compared with placebo. For all efficacy variables, aselizumab presented no significant trends but only a few scattered statistically significant differences between groups.